Our solutions help improve patient outcomes and clinical performance one therapy-one patient at a time.
Increased sales and positive EBITDA conclude a good start for 2023
FIRST QUARTER (JAN-MARCH 2023) RESULTS
• Order intake amounted to 57.7 (54.4) MSEK.
• The orderbook by the end of the period was 126.2 (91.4) MSEK, whereof 66.2 MSEK is revenue expected in 2023.
• Net sales amounted to 65.0 (53.1) MSEK, an increase of 22%, whereof 15% organic.
• Earnings before interest, tax, depreciation and amortization (EBITDA) totaled 7.3 (-1.3) MSEK.
• Net income for the period amounted to -1.5 (-7.4) MSEK.
• Earnings per share (EPS) were -0.06 (-0.30) SEK.
• Cash flow from operating activities totaled 1.2 (11.2) MSEK.
Comments by the CEO Göran Malmberg
"We expect over time to be able to improve our EBITDA margins compared to 2022 combined with an ambition to receive further benefits from our program related to efficiency. For 2023 we expect strong performance from medical device industry business combined with the expectation that the demand from the hospital related business will continue at least at similar levels to 2022."
Trading information
Short name for Nasdaq First North Growth Market : MNTC
ISIN-code: SE0012673291
The shares are registered by Euroclear Sweden AB
Advisor
FNCA Sweden AB is the Certified Advisor for the company
Important information about Nasdaq First North Growth Market Nasdaq
First North Growth Market is an alternate trading platform managed as a separate organization within NASDAQ Group. Companies listed on Nasdaq First North Growth Market is not managed under the same set of rules as the regulated main list market. The companies follow less complex set of rules and procedures adapted for small growth companies. The risk involved with investment in companies on First North Growth market can therefore be higher than investing in companies on the main market. All companies with shares that is traded on Nasdaq First North Growth Market has a certified advisor that secure and control that the rules are followed.
____________________________________________________________________________________________________________________________________
Financial targets (short-medium term)
Revenue Growth
30 - 40% average annual revenue growth during short to medium terms (next 3-5 years).
Profitability
30% EBITDA margin within short to medium term (3-5 years).
Dividend Policy
Mentice is a company on a rapidly growing market. To capitalize on its market opportunities, the company will prioritize growth, both organic and through acquisitions.
Dividends
The company has no history of Dividend.
03
February
2023
27
April
2023
11
Maj
2023
20
July
2023
26
October
2023